HCPCS Level II code Q0155 describes a single-unit dose of dronabinol (Syndros) 0.1 mg oral provided as an FDA‑approved prescription anti‑emetic intended for use as a complete therapeutic substitute for an intravenous anti‑emetic at the time of chemotherapy treatment; the service is an oral anti‑emetic medication administration used during chemotherapy sessions and the typical site of service is the outpatient oncology infusion clinic or chemotherapy treatment area with a dosing regimen not to exceed 48 hours.

For related coverage guidance, see recent payer policy updates: B-Hemolytic Streptococcus Testing, Human Immunodeficiency Virus (HIV) — Coverage Criteria for Testing and Resistance Assays, Hepatitis Testing (A, B, C, D) Coverage Criteria.